The most commonly prescribed targeted therapy in this study was everolimus, which largely reflects the prevalence of phosphatidylinositol 3-kinase/mammalian targets of rapamycin (PI3K/mTOR) pathway alterations in the breast cancer population. This evidence concerns the gene MTOR and breast carcinoma.